We are continuously working to strengthen our pipeline with early as well as late-stage assets addressing underserved dermatological disease areas. Ultimately, we aim to make a fundamental …

On our way towards the most innovative pipeline We offer important standard treatments, as well as new innovative solutions for skin diseases. We have built one of the strongest pipelines in eczema and …

Feb 18, 2026 · The pipeline was expanded with new late stage trials of Anzupgo® (delgocitinib cream) in adults with palmoplantar pustulosis and lichen sclerosus, as well as the addition of an ongoing Phase …

Feb 26, 2025 · LEO Pharma’s performance last year puts it on track to meet its ambitions for sustainable, profitable growth and innovation, as set out in 2021, when the company embarked on a …

2 days ago · LEO Pharma delivers 9% revenue growth at CER in Q1 2026 and strengthens innovation pipeline

PRESS RELEASE LEO Pharma delivers 9% revenue growth at CER in Q1 2026 and strengthens innovation pipeline

May 15, 2025 · "We have seen a good start to 2025, with encouraging progress in the ongoing launch of Anzupgo® and key milestones achieved for our innovation pipeline. A significant highlight is the …

We are continuously working to strengthen our pipeline with early as well as late-stage assets addressing underserved dermatological disease areas. Ultimately, we aim to make a fundamental …

We are continuously working to strengthen our pipeline with early as well as late-stage assets addressing underserved dermatological disease areas. Ultimately, we aim to make a fundamental …

Aug 18, 2025 · This reflects the FDA approval of Anzupgo® and year-to-date business performance. The outlook does not include any impact from the partnership for SPEVIGO®, pending closing of the …